ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

364
Analysis
Health CareChina
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
Refresh
06 Oct 2021 09:02

Pre-IPO TransThera Sciences (Nanjing) - Insights on the Industry, the Business and the Concerns

This article mainly analyzed TransThera in terms of the industry characteristics of small molecule drug market, candidates in the pipeline (TT...

Logo
225 Views
Share
04 Oct 2021 13:23

Hopson (754 HK) To Buy 51% of Evergrande Property Services? Upcoming MGO & Potential HSCEI Changes

Hopson is reportedly looking to buy 51% in Evergrande Prop Serv for more than HK$40bn.That is a 41.7% premium to the last close and will trigger an...

Logo
410 Views
Share
04 Oct 2021 08:23

China Healthcare Weekly (Oct.1) - A Landmark Document Released, Dental Implants, Core Data Security

The insight analyzed a landmark document about medical insurance plan for the next four years,the direction and the coverage of basic medical...

Logo
238 Views
Share
bearishAbbisko Cayman
30 Sep 2021 15:44

Abbisko IPO: Valuation Insights

Abbisko plans to raise $204m (net) at the mid-point of the IPO price range. Our valuation analysis suggests that the IPO price range is full and we...

Logo
330 Views
Share
bullishAbbisko Cayman
23 Sep 2021 15:48

Abbisko IPO: A Promising but Longer Term Prognosis

While both core products are at an early stage of development, promising trials, management’s track record and blue-chip backers suggest that the...

Logo
397 Views
Share
x